Case Report
An Adult Patient with Systemic Mastocytosis and B-Acute Lymphoblastic Leukemia
Table 1
Hematological response of our patient to imatinib mesylate (IM).
| | | Day of assessment of response following induction (concurrent G-CSF usage) | Initiation of IM 6 days later (cessation of G-CSF) | 5 days following introduction of IM (without G-CSF or transfusional support) | 8 days following introduction of IM (without G-CSF or transfusional support) | 15 days following introduction of IM (initiation of salvage therapy) |
| | Hemoglobin (gr/dL) | 7.2 | 8.6 | 11.7 | 12.3 | 11.2 | | Neutrophils (/μL) | 0.0 | 1100 | 3600 | 4180 | 2900 | | Platelets (/μL) | 11000 | 16000 | 91000 | 180000 | 170000 |
|
|
G-CSF; granulocyte-colony stimulating factor.
|
